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The pharmacokinetics of oral fluoroquinolone antibiotics in normal volunteers have been studied extensively;
however, limited patient data exist. Enoxacin steady-state pharmacokinetics and bioavailability were deter-
mined following repeated 400-mg intravenous (i.v.) and oral dosing by using compartmental and noncompart-
mental methods in 10 elderly (mean age, 73.8 years) men with complicated urinary tract infections. Average
peak enoxacin concentrations following i.v. and oral dosing were 8.15 and 5.45 mg/liter, respectively. Mean
values for major pharmacokinetic parameters (noncompartmental) were similar following i.v. and oral
administration, respectively: area under the concentration-time curve from 0 to 12 h, 47.6 and 41.0
mg * h/liter; volume of distribution or volume of distribution/bioavailability, 1.61 and 1.99 liters/kg; total body
clearance or total body clearance/bioavailability, 2.58 and 3.01 ml/min per kg; and half-life, 8.2 and 9.1 h.
Parameters from analysis of enoxacin plasma concentration data by using a two-compartment pharmacokinetic
model also revealed marked similarities between the two administration routes. Enoxacin was highly
bioavailable (mean, 86.97%) following oral administration.
Enoxacin is a new naphthyridine fluoroquinolone antibi-
otic with potent activity in vitro against many gram-positive
and gram-negative bacteria (10, 18). Studies in normal vol-
unteers have demonstrated that the bioavailabilities of sev-
eral newer fluoroquinolones, including enoxacin, exceed
70% (12, 16, 22); however, the pharmacokinetics and bio-
availabilities of many of these agents in elderly infected
patients are not known. This study examined the pharmaco-
kinetics of enoxacin in a group of elderly patients with
complicated urinary tract infections (UTIs) who received
enoxacin as an intravenous (i.v.)-to-oral regimen.
MATERIALS AND METHODS
Patients. The patient population comprised elderly men
with complicated UTIs enrolled in a clinical trial evaluating
the efficacy of enoxacin. A complicated UTI was defined by
the presence of one or more of the following: urinary tract
obstruction, urologic malignancy, neurogenic urologic dis-
ease, or recent instrumentation of the genitourinary tract.
Patients excluded from the study included those with termi-
nal illnesses or concomitant infections potentially precluding
evaluation of response, liver function tests or a serum
creatinine greater than twice the upper limit of normal,
inability to accept orally administered medications, chronic
antacid therapy, and a known or suspected allergy to quino-
lones.
Drug administration. Patients were initially treated with
400 mg of enoxacin i.v. every 12 h. The drug was diluted in
250 ml of 5% glucose in water and infused into a peripheral
vein over 1 h by using a constant-rate infusion pump. The
* Corresponding author.
i.v. tubing was flushed with an additional 20 ml of 5%
glucose in water at the end of the infusions to ensure
complete delivery of the dose. After at least 72 h of parent-
eral therapy, patients were changed to oral therapy with
400-mg enoxacin tablets every 12 h. The total duration of
therapy was 10 to 14 days.
Timing of pharmacokinetic studies. Pharmacokinetic stud-
ies were performed after patients had received five or more
doses by the i.v. and oral routes to assess steady-state
pharmacokinetic conditions. Trough blood samples for
enoxacin were obtained from all patients prior to the admin-
istration of the two doses preceding the study dose to
confirm steady-state pharmacokinetic conditions. On days of
pharmacokinetic study, patients were fasted overnight and
for at least 2 h after administration of study doses.
Sample collection. Following the i.v. doses, blood samples
were obtained from an indwelling intravenous cannula (hep-
arin lock) at the following times: predose; 30 min (midinfu-
sion); 1.0 h (end of infusion); and 1.08, 1.25, 1.5, 2, 3, 4, 6,
8, 10, and 12 h after the start of the infusion. After oral
doses, samples were collected predose and at 0.25, 0.5, 0.75,
1, 1.5, 2, 3, 4, 6, 8, 10, and 12 h after administration. Samples
were centrifuged for 20 min; and the plasma was removed,
divided into portions in small polypropylene tubes, and
frozen at -20°C until it was assayed. For both i.v. and oral
study doses, urine was collected and pooled over the follow-
ing intervals: 0 to 4, 4 to 8, and 8 to 12 h after the start of the
i.v. infusion or administration of the oral dose, respectively.
Urine volumes were recorded, and portions were frozen at
-20°C until the time of assay.
Drug assay. The enoxacin concentrations in plasma and
urine were determined by high-performance liquid chroma-
tography (HPLC). The mobile phase consisted of a mixture
1966
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of HPLC-grade acetonitrile (Aldrich Chemical Co., Inc.,
Milwaukee, Wis.) with an ion-pair reagent (16:84 [vol/vol).
The ion-pair reagent was prepared by combining 21 g of
citric acid monohydrate (Fisher Scientific Co., Fairlawn,
N.J.) and 1 g of ammonium perchlorate (Aldrich) in a 1-liter
flask. To this dry fraction, 1.15 ml of tetrabutylammonium
hydroxide (Aldrich) in 100 ml of HPLC-grade water was
added and further diluted to 1 liter with water. This mixture
was then degassed by filtering it twice through 0.2-,um-pore-
size Nylon-66 filters (Rainin Instrument Co., Woburn,
Mass.) under vacuum.
A reversed-phase, 25-cm, partisil 5 ODS-3 analytical col-
umn (Whatman International Ltd., Maidstone, England) was
used. The mobile phase was passed through the column at a
flow rate of 1.0 ml/min. A hand-packed guard column of C-18
pellicular material (Whatman), which was repacked with
fresh material every 2 to 3 assay days, was also used. The
UV A340 was detected (model 481 LC spectrophotometer;
Waters Associates, Inc., Milford, Mass.). Enoxacin stan-
dards in plasma or urine were prepared fresh each assay day.
Standard concentrations in plasma ranged from 0.2 to 5.0
mg/liter, while standard concentrations in urine ranged from
10 to 300 mg/liter. Norfloxacin (Merck Sharp & Dohme,
West Point, Pa.) stock solutions of 30 and 100 mg/liter were
used as internal standards in the plasma and urine assays,
respectively.
Plasma standards and samples were prepared by pipetting
0.4 ml of plasma, 0.1 ml of water, and 0.02 ml of internal
standard into a 2-ml polypropylene centrifuge tube. Protein
precipitation with 0.1 ml of acetonitrile-perchloric acid (4:1
[vol/vol]) was followed by a 10-min centrifugation at 700 x g
(IEC, Needham Heights, Mass.) at 25°C. The supernatant
was used for assay. Urine standards and samples were
prepared by adding 0.1 ml of urine to 0.8 ml of HPLC-grade
water and 0.1 ml of internal standard.
Column retention times for norfloxacin and enoxacin were
7.5 and 9.0 min, respectively. Enoxacin and norfloxacin
peak heights were calculated and recorded by using an
electronic integrator (LCI 100; The Perkin-Elmer Corp.,
Norwalk, Conn.). Peak height ratios (enoxacin to norflox-
acin) were calculated and regressed against concentrations
of known standards by least-squares linear regression.
The within- and between-day coefficients of variation for
assay precision of three plasma controls containing 0.25, 1.0,
and 3.0 mg of enoxacin per liter were 7.93, 3.63, and 4.54%,
respectively (triplicate injections on three separate days for
nine injections per control sample). The accuracies of these
same controls during assay of patient samples averaged 4.8,
2.6, and 3.4% (range, -4.0 to 8.0%) variations from target
values, respectively. Similarly, for three urine controls con-
taining 20, 50, and 200 mg of enoxacin per liter, the within-
and between-day coefficients of variation were 3.84, 4.94,
and 2.74%, respectively (triplicate injections on three sepa-
rate days for nine injections per control sample). Mean
accuracies of urine controls over 5 assay days averaged 3.8,
3.2, and 1.6% (range, 5.2 to 8.5%) variations from target
values, respectively.
Pharmacokinetic analysis. Enoxacin plasma concentration
data were analyzed by using both noncompartmental and
compartmental methods. The areas under the zero and first
moments of the enoxacin plasma concentration-time curve
were calculated by using the linear trapezoidal rule method.
The linear portion of the terminal phase of individual log-
linear concentration-time plots was determined by visual
inspection. The terminal slope (X,) was then calculated by
using unweighted, linear least-squares regression analysis.
Total body clearance (CL) and steady-state volume of dis-
tribution were calculated by using standard pharmacokinetic
equations (7, 20). Renal clearance (CLR) was determined by
dividing the amount of unchanged drug excreted in the urine
during the collection interval by the corresponding area
under the plasma concentration-time curve (AUC). Nonre-
nal clearance was calculated by subtracting CLR from CL.
Bioavailability (F) was calculated by dividing the AUC
following oral administration by the AUC following the i.v.
dose. To correct for potential intrasubject variability in drug
clearance following i.v. and oral dosings, a corrected bio-
availability was also calculated by multiplying F by the ratio
of the half-lives (tQ12) (i.v.:oral) (7).
Enoxacin plasma concentration data were also analyzed
by using an open, two-compartment pharmacokinetic model
by using extended least-squares regression with the com-
puter program MKMODEL (11). The decision to use a
two-compartment model over a more simple model was
based on comparisons of the Schwartz criterion for the fitted
data (11, 19). The variance [var(l)] in the predicted drug
concentration was given by SD2 x (VO + YPWR), where SD
is a standard deviation scale factor calculated by the pro-
gram, Yis the structural model prediction, VO is the variance
independent of Y (i.e., "background noise") fixed at a very
small value, and PWR is the power parameter (constrained
between 0 and 3). Standard equations were used to correct
for infusion time and to calculate microscopic rate constants.
In fitting plasma concentration data following oral doses,
unrealistic estimates of the volume of the central compart-
ment (V1) were often generated. This was due to problems
with parameter identifiability; computer-generated estimates
for V1, the absorption rate constant, and the distribution rate
constant were highly correlated with one another and had
large confidence intervals. To overcome this parameter
identifiability problem, Bayesian constraints were applied to
V1 when individual oral data sets were fitted based on a
priori estimates of V1 from the i.v. dose for that patient. The
constraint was applied by using a penalty to the objective
function if values for this parameter exceeded the initial
estimate by more than 20% (11).
Creatinine clearance (CLCR) was calculated for each pa-
tient by the method of Cockcroft and Gault (4). Unweighted,
linear least-squares regression analysis was used to correlate
CLCR with enoxacin CL and CLR, and the statistical signif-
icance of the regression coefficients was determined. The
regression line for the correlation of CLCR with enoxacin
CLR was forced through the origin.
Response to therapy. Clinical and microbiological re-
sponses in patients were assessed 1 week after the comple-
tion of therapy. Clinical effectiveness was assessed as fol-
lows: cure, disappearance of base-line signs and symptoms
relative to the acute episode; improvement, remission but
not complete disappearance of base-line signs and symp-
toms; and failure, no significant change in base-line signs or
symptoms. Microbiological response was assessed as fol-
lows: cure, negative urine culture for the original infecting
organism; failure, positive culture for the original infecting
organism; and superinfection, eradication of the initial in-
fecting pathogen but a positive culture for a different patho-
gen.
This protocol was approved by human research review
committees at the participating institutions, and informed
consent was obtained from the patients according to estab-
lished guidelines.
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TABLE 1. Characteristics of study patients
Patient no. Age (yr) Wt (kg) Calculated CLCR Urologic complicationPatiento. (yr) (kg)
~~~~~~~~~~(ml/min)
1 65 51.1 53 Chronic Foley catheter
2 75 54.2 18 Prostate cancer
3 70 58.2 56 Prostate resection
4 64 61.0 64 Prostatic hypertrophy
5 87 59.1 43 Prostate cancer
6 88 56.8 27 Prostatic hypertrophy
7 63 77.3 74 Prostatic hypertrophy
8 92 61.4 34 Prostatic hypertrophy
9 57 72.7 84 Neurogenic bladder
10 77 81.8 45 Prostate cancer
Mean + SD 73.8 + 12.0 63.4 ± 10.3 49.8 ± 20.7
RESULTS
Demographic data for the 10 patients who completed the
study are given in Table 1. The patients were elderly men
(mean age, 73.8 years) who had renal functions consistent
with their advanced age (mean calculated CLCR, 49.8 ml/
min) at the time of entry into the trial. Based on height
measurements, all patients were within 20% of their ideal
body weight.
Figure 1 depicts enoxacin concentrations in plasma of the
10 patients following i.v. and oral administration. Mean
trough concentrations at 24 and 12 h prior to administration
of the study doses confirmed that steady-state pharmacoki-
netic conditions were obtained. Enoxacin concentrations in
plasma and calculated pharmacokinetic parameters in pa-
tient 2 varied substantially (often, greater than 3 standard
deviations) from values obtained in the other nine patients
studied. Patient 2 had relatively poor renal function on entry
into the trial (Table 1) and experienced acute, unexplained
increases in his blood urea nitrogen and serum creatinine
along with electrolyte abnormalities during the study that
were not thought to be related to enoxacin. Because this
patient was thought to be an outlier, parameter values for
this patient were excluded when means for the study popu-
lation were calculated. Parameter values for patient 2 are
included in the reported ranges in Table 2.
When data for patient 2 were excluded from the group
analysis, mean (range) peak and trough enoxacin concentra-
tions in plasma following i.v. and oral dosing were 8.15
16
14
12
10
8
6
4
2
0
Concentration (mg/L)
-24 -12 0 2 4 6
Time (hrs)
8 10 12 14
FIG. 1. Enoxacin concentrations (mean + standard deviation) in
plasma at steady state in nine patients following 400-mg i.v. (U) and
oral (+) doses. The i.v. (*) and oral (l) data for patient 2 are
depicted separately.
mg/liter (range, 5.5 to 11.1 mg/liter) and 2.31 mg/liter (range,
0.4 to 4.7 mg/liter) and 5.45 mg/liter (range, 2.3 to 6.6
mg/liter) and 2.19 mg/liter (range, 0.5 to 4.7 mg/liter), respec-
tively, in the nine patients. The mean time to reach peak
concentrations following oral dosing was 2 h, but it varied
between 0.5 and 6 h. This variability in time to reach peak
concentrations accounts for an artifactual "second peak" in
the mean plasma enoxacin concentration-time curve follow-
ing oral dosing (Fig. 1); a second peak was not observed in
individual curves.
The oral F of enoxacin in these patients ranged between
66.5 and 113.1%, with an average of about 87% (Table 2).
Application of a correction factor to the AUC ratios for
slight changes in noncompartmental elimination t1/2 (t0122)
between the i.v. and oral phases had little impact on the
calculated bioavailability. The mean fractions of the admin-
istered dose excreted unchanged in the urine in six patients
with complete 12-h urine collections were 50.6 and 50.0%
following i.v. and oral dosing, respectively, when corrected
for F.
Noncompartmental pharmacokinetic analysis. Noncom-
partmental pharmacokinetic data were analyzed following
i.v. and oral administration, and the results are given in
Table 2. Enoxacin disposition was consistent within each
patient, as evidenced by marked similarities in major phar-
macokinetic parameters following parenteral and oral admin-
istration. The apparent volumes of distribution (Varea or
Varea/F) averaged 1.6 liters/kg (range, 1.0 to 2.4 liters/kg) and
2.0 liters/kg (range, 1.4 to 3.2 liters/kg) following i.v. and oral
administration, respectively. The mean t1/2, was approxi-
mately 8 to 9 h following the two administration routes. The
estimated t1/2,s in patient 2 were 14.9 and greater than 38 h
following i.v. and oral dosing, respectively.
High concentrations of enoxacin were present in urine
following i.v. and oral administration. Mean + standard
deviation concentrations of enoxacin in urine over the
intervals of 0 to 4, 4 to 8, and 8 to 12 h following the i.v. dose
were 446 ± 309, 359 ± 106, and 322 ± 172 mg/liter,
respectively. Following oral dosing, concentrations of enox-
acin in urine were 376 ± 214, 442 ± 286, and 264 ± 124
mg/liter, respectively, over the same collection intervals.
In the nine patients included in the group analysis, enox-
acin CL (or CL/F following oral dosing) averaged 2.58
ml/min per kg (range, 1.0 to 4.84 ml/min per kg) and 3.01
ml/min per kg (range, 1.50 to 6.07 mllmin per kg) following
i.v. and oral dosing, respectively. The enoxacin CLR was
approximately 1.4 ml/min per kg by either route of adminis-
tration and explained approximately half of the CL. The
.16
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FIG. 2. Correlation of CLCR with enoxacin CL following i.v. and
oral dosings in nine patients. Connected points indicate values from
an individual patient for their i.v. (-) and oral (*) doses. (CL
[ml/min] = 3.53 x CLCR [mlmin] - 8.12) (r2 = 0.46; P < 0.005).
mean enoxacin CLR in these patients was approximately 1.8
times greater than the mean calculated CLCR. Enoxacin CL
and CLR in patient 2 were 1.02 and 0.19 ml/min per kg,
respectively. Figures 2 and 3 depict the intrapatient variabil-
ity in enoxacin CL and CLR and their relation with CLCR,
respectively. In both cases, statistically significant correla-
tions were found.
Compartmental pharmacoldnetic analysis. Results of the
analysis of pharmacokinetic data by using a two-compart-
ment body model are given in Table 3. Values for major
pharmacokinetic parameters derived from compartmental
analysis, including CL, volume of distribution at steady
state, and compartmental elimination t1/2 (tl,2/2) were similar
to those obtained by noncompartmental methods. V1 was
found to be about 0.5 liter/kg; a large extravascular compart-
ment of between 0.89 and 1.26 liters/kg was also noted.
Clinical response. The infecting organisms and clinical
response to enoxacin therapy in the 10 study patients are
shown in Table 4. Patient 2 died prior to the assessment of
response. All nine evaluable patients had a favorable clinical
response; eight were cured and one was classified as im-
proved at the evaluation on day 7. Microbiologically, the
original pathogen(s) was eradicated from five of the nine
evaluable patients; three patients were found to be superin-
fected (two with yeasts and one with Serratia marcescens) 7
days after enoxacin treatment. Enoxacin failed to eradicate
any initial pathogens from one patient with a chronic,
Enoxaln Renal Cleaance (ml/min)
0 20 40 60 s0 100
Cneinine Clearance (ml/min)
FIG. 3. Correlation of CLCR with enoxacin CLR following i.v.
and oral dosings in nine patients. Connected points indicate values
from an individual patient for their i.v. (-) and oral (*) doses (CLR
[ml/min] = 1.74 x CLCR [ml/min]) (r2 = 0.60; P < 0.005).
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TABLE 3. Parameters from compartmental pharmacokinetic analysis of enoxacin under steady-state conditions
following i.v. and oral administrationa
Dose V1 (liter/kg) CL (ml/min per kg) a (h-') l (h-1) t4/20 (h)
i.v.b 0.47 ± 0.15 (0.21-0.71) 2.68 ± 1.15 (1.12-4.68) 4.64 ± 3.52 (1.14-11.55) 0.11 ± 0.04 (0.06-0.16) 7.42 ± 3.44 (4.36-12.60)
Oralc 0.56 ± 0.17 (0.33-0.78) 3.16 ± 1.73 (1.18-6.98) 6.99 ± 3.57 (1.93-12.50) 0.10 ± 0.05 (0.04-0.20) 8.42 ± 4.51 (3.46-15.75)
a Values are means ± standard deviations; ranges are included in parentheses. Abbreviations: V1, volume of the central compartment; CL, total body
clearance; a, distribution rate constant; ,, elimination rate constant; t1/2P, compartmental elimination half-life; klo, k12, and k2j, elimination rate constants from
central compartment, from central to peripheral compartment, and from peripheral to central compartment, respectively; V.., volume of distribution at steady
state; VT, volume of the extravascular compartment. For oral doses, values for V1, CL, volume of distribution at steady state, and volume of the extravascular
compartment represent the value divided by F.
b Patients 2 and 8 were excluded from group analysis (concentration-versus-time data were not described by the two-compartment model).
c Patients 2 and 6 were excluded from group analysis (concentration-versus-time data were not described by the two-compartment model).
indwelling urinary catheter, despite mean enoxacin concen-
trations in urine of 250 to 350 mg/liter following i.v. and oral
dosings, respectively. No pharmacokinetic variables ap-
peared to be associated with the clinical or microbiological
response in these patients.
DISCUSSION
Increased emphasis has been placed on the evaluation
of pharmacokinetic and pharmacodynamic characteristics
of newer antimicrobial agents in populations likely to re-
ceive treatment with the agent (21). The pharmacokinetics
of the fluoroquinolones have been extensively studied
in young, normal volunteers or young patients; however,
relatively few studies have characterized the disposition
of these compounds in elderly patients receiving therapy
with these drugs. Issues such as the reliability of oral
absorption and the absence of drug accumulation are impor-
tant considerations for the use of these drugs in this patient
population.
In this study, high enoxacin bioavailability was demon-
strated in elderly infected patients. Following the distri-
bution and absorption phases after i.v. and oral adminis-
tration, respectively, enoxacin plasma concentration-versus-
time curves were practically superimposable. The amount
of drug excreted in urine, another marker of drug absorp-
tion for agents excreted by the renal route, further demon-
strated excellent bioavailability following oral dosing.
Marked variability in the time to reach maximum concen-
tration in plasma following oral dosing was observed; how-
ever, the variation in absorption time did not appear to affect
the overall extent of enoxacin absorption within each pa-
tient.
These results are comparable to those of other investiga-
tions of enoxacin pharmacokinetics in elderly patients. In a
group of 19 patients (ages, 61 to 84 years)
with complicated UTIs, Naber and colleagues (15) reported
a mean peak concentration in plasma of 3.55 mg/liter
with a mean t4/2, of 7.3 h (range, 3.7 to 38.5 h) following a
single 400-mg oral dose. Wise et al. (24) reported steady-
state peak concentrations of enoxacin of 2.80 mg/liter and a
mean tl2, of 6.7 h after repeated oral dosing of 200 mg twicedaily in a group of 23 patients greater than 70 years of age
with UTIs.
In evaluating the pharmacokinetics of enoxacin in our
elderly patients, a smaller V and decreased CLR were noted
with the values reported in younger subjects. These phar-
macokinetic differences are likely due to the well-described
changes in physiology associated with advancing age, par-
ticularly decreases in total body water and lean body mass
and, perhaps most importantly, a decline in renal function (9,
14). These changes result in higher peak drug concentra-
tions, larger AUCs, and prolonged t1/2S of certain drugs in
this patient population (9, 14). The change in enoxacin CLR
with CLCR in our patients was similar to that observed by
others studies in which elderly patients as well as younger
patients with renal impairment were evaluated (3, 17, 23).
The relation between decreased enoxacin clearance with
declining renal function was vividly demonstrated in patient
2 in this study, highlighting the importance of dosage alter-
ations in similar patients.
A few studies have directly compared fluoroquinolone
pharmacokinetics in young and elderly subjects. For a single
600-mg oral dose of enoxacin, Dobbs et al. (5) found that
maximum concentrations in plasma and AUCs were statis-
tically higher in a group of elderly subjects compared with a
group of younger controls; however, enoxacin t1/2s were not
different between the groups (7.34 and 6.75 h for the young
and elderly subjects, respectively). Other investigations of
ofloxacin (8) and pefloxacin (6) (fluoroquinolones with mark-
edly different mechanisms of elimination [17]) revealed sig-
nificant pharmacokinetic differences between young and
elderly subjects. Substantially higher peak drug concentra-
tions and prolonged drug elimination were found in the
elderly subjects in both studies.
Comparative pharmacokinetic studies of ciprofloxacin (an
agent similar to enoxacin in that excretion is balanced
TABLE 4. Clinical and microbiological responses to enoxacina
Patient Infecting Clinical Microbiological
no. organism(s) response response
1 Enterobacter cloacae, Cure Failure
Pseudomonas aerugi-
nosa, Klebsiella pneu-
moniae
2 Pseudomonas aerugi- Unevaluable Unevaluable
nosa, Enterococcus
sp.
3 Proteus vulgaris Cure Cure
4 Escherichia coli Cure Cure
5 Klebsiella pneumoniae Cure Superinfectionb
6 Escherichia coli Cure Cure
7 Escherichia coli Cure Cure
8 Proteus mirabilis Improve- Superinfectionc
ment
9 Pseudomonas aerugi- Cure Cure
nosa
10 Providencia rettgeri, Cure Superinfectionc
Proteus mirabilis
a Response evaluations were made 5 to 9 days after the completion of
therapy.
b Superinfection was due to Serratia marcescens.
c Superinfections were due to yeasts.
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TABLE 3-Continued
klo (h'-) k12 (h-1) k2l (h-1) Vs. (liters/kg) VT (liters/kg)
0.40 ± 0.24 (0.13-0.84) 3.07 ± 2.74 (0.57-8.68) 1.28 ± 0.69 (0.49-2.19) 1.36 ± 0.28 (1.02-1.73) 0.89 ± 0.21 (0.64-1.24)
0.39 ± 0.29 (0.11-0.97) 4.61 ± 2.56 (1.02-7.69) 2.09 ± 1.47 (0.74-5.49) 1.81 ± 0.67 (1.33-3.41) 1.26 + 0.65 (0.72-2.71)
between renal and nonrenal mechanisms) in young and
elderly subjects also indicate age-related differences. Ball
and co-workers (1) found significantly greater maximum
concentratiQns in serum and AUCs in an elderly group of
Ratients following single 100-mg oral doses. LeBel et al. (13)
studied ciprofloxacin pharmacokinetics in young and elderly
(age;- 70 to 86 years) subjects following single 500-mg oral
doses. Mean peak concentrations in serum 8 h after dosing
and mean AUCs were found to be significantly higher in the
elderly subjects. The t1/2 was approximately double in the
elderly patient group (6.8 h) compared with that in the young
volunteers,. (3.7 h). These differences were explained by
significantly smaller volumes of distribution at steady state
and reduced clearances (both CLR and nonrenal clearance)
in the elderly patient group compared with those in the
younger subjects.
The clinical significance of these pharmacokinetic differ-
ences between young and elderly individuals may be realized
only through integration with the dose- or concentration-
related adverse. effects and pharmacodynamic characteris-
tics of the fluoroquinolones. Correlations between fluoroqui-
nolone concentrations and adverse effects, such as those of
the central nervous system, remain poorly defined. Wolf et
al. (25j noted that higher doses -of enoxacin (1,600 mg),
which resulted in peak concentration's in serum of 7 to 8
mg/liter, were associated with adverse central nervous sys-
tem effects (dizziness) in several volunteers more frequently
than lower doses were. Further studies are needed to better
define the possible relations between concentrations of drug
in serum and adverse effects.
In vitro and animal studies evaluating the pharmacokinet-
ics of the antibacterial activities of fluoroquinolones suggest
that dosing regimens that produce high peak concentrations
may be optimal. This suggestion is based on a number of
characteristics of the fluoroquinolones, including concentra-
tion-dependent killing and the observation of a significant
postantibiotic effect in vitro and in vivo against a number a
bacteria (M. N. Dudley, Postgrad. Med., in press). In addi-
tion, high peak concentrations have been shown to reduce
the emergence of resistant subpopulations in an in vitro
model of infectiond(2). To take advantage of these pharma-
cokinetic and pharmacodynamic characteristics, particularly
in elderly patients, the optimal dosing strategy for these
antibiotics may be through administration of usual doses less
frequently (i.e., once daily), since a given dose in elderly
patients produces a higher peak concentration (compared
with that in a young individual) and elimination of the drug is
prolonged.
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